Satisfaction and usability of the recombinant chorionic gonadotropin prefilled pen: a survey in Italy

Article Details

Authors
Chiara Dallagiovanna, Laura Mensi, Luca Di Gesaro, Irene La Vecchia, Marco Reschini

Article Type
Original Research

DOI
10.7573/dic.2021-10-3

Related Articles

Article Page

Abstract

Background: Due to high purity, recombinant human chorionic gonadotropin (hCG) is suitable for subcutaneous injection, and hence for self-administration, in assisted reproduction. To increase usability and reduce the risk of dosing errors, a prefilled pen was produced. We investigated the ease of administration and satisfaction with the product amongst patients and healthcare professionals.

Methods: A survey was conducted amongst women with infertility who underwent in vitro fertilization treatments with recombinant hCG to trigger ovulation in various clinics in Italy.

Results: A total of 276 Italian women were interviewed. The median score of preference for the prefilled pen in comparison with hCG powder to be reconstituted in the solvent was rated as 9 (range 8–10), and 125 women answered that the prefilled pen had major advantages. Reasons for preference of the prefilled pen were linked to ease of use and safety: avoidance of dosage mistakes and of concern of such, ease of administration, certainty that the drug is correctly taken, safe administration and no anxiety. The procedure for recombinant hCG administration through the prefilled pen was judged as easy by 80% of respondents, with a median score of 9 (range 8–10) for easiness on a 1–10 scale. Out of 276 respondents, 249 (90%) had no problem with the injection.

Conclusion: Overall, the respondents reported a favourable perception of the prefilled pen with hCG, which was reported to be easy to use and perceived to prevent dosage mistakes.

Keywords: assisted reproduction, human chorionic gonadotropin, prefilled pen, survey.

Citation: Dallagiovanna C, Mensi L, Di Gesaro L, La Vecchia I, Reschini M. Satisfaction and usability of the recombinant chorionic gonadotropin prefilled pen: a survey in Italy. Drugs Context. 2022;11:2021-10-3. https://doi.org/10.7573/dic.2021-10-3

Contributions: Study conception and design: MR, CD; collection and interpretation of data: ILV and LDG; statistical analysis: MR; manuscript drafting: LDG and LM; manuscript editing: CD. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: MR reports personal fees from Merck Serono. All the other authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/12/dic.2021-10-3-COI.pdf

Acknowledgements: Editorial assistance was provided by Laura Brogelli, PhD, and Aashni Shah (Polistudium Srl, Milan, Italy), and this activity was supported by Doxa Pharma, Milan, Italy.

Funding declaration: The study was funded by Merck Serono.

Copyright: Copyright © 2021 Dallagiovanna C, Mensi L, Di Gesaro L, La Vecchia I, Reschini M. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Dallagiovanna C, Mensi L, Di Gesaro L, La Vecchia I, Reschini M. https://doi.org/10.7573/dic.2021-10-3. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/satisfaction-and-usability-of-the-recombinant-chorionic-gonadotropin-prefilled-pen-a-survey-in-italy

Correspondence: Marco Reschini, Infertility Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via M. Fanti, 6 – 20122, Milan, Italy. Email: marco.reschini@policlinico.mi.it

Provenance: Submitted; externally peer reviewed.

Submitted: 5 October 2021; Accepted: 2 December 2021; Publication date: 26 January 2022.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF